CASI Pharmaceuticals (CASI) AI Stock Analysis

• Market Cap: $28.97M
• Dividend Yield: N/A
• Average Volume (3M): 8.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: 11.40%
• EPS Growth: -18.18%
• Country: US
• Employees: 233
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.69
• Shares Outstanding: 15,492,681
• 10 Day Avg. Volume: 8,268
• 30 Day Avg. Volume: 8,397
• PEG Ratio: 0.03
• Price to Book (P/B): 15.78
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.31
• Enterprise Value/Revenue: 0.36
• Enterprise Value/Gross Profit: 3.23
• Enterprise Value/Ebitda: -0.36
• 1Y Price Target: $4.00
• Price Target Upside: 113.90% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: ―

CASI Pharmaceuticals faces substantial financial difficulties, with declining revenues and increasing losses, reflected in a low financial performance score. The technical analysis indicates a bearish trend, and the valuation is unattractive due to negative earnings and lack of dividends. These factors contribute to a low overall stock score, highlighting the need for significant improvements in operational efficiency and revenue growth.

Positive Factors

Debt Reduction

The sale of the China business to Kaixin allows the company to eliminate $20M of existing debt, improving its financial position.

Drug Development

CID-103 has shown superior activity and reduced toxicity compared to existing CD38 inhibitors in preclinical and Phase 1 studies, indicating strong potential for successful development.

Negative Factors

Business Operations

The company received a Termination Process Letter to withdraw the Evomela license following a wind-down period, which impacts the company's Chinese business revenues.

Financial Performance

CASI reported a net loss of $0.69 per share for the quarter, which is higher than the consensus estimated net loss of $0.61 per share.

Revenue Decline

The company reported lower-than-expected revenues, which fell 16% year-over-year, primarily due to increased generic competition for Evomela in China.

CASI Pharmaceuticals Business Overview & Revenue Model

Company Description

CASI Pharmaceuticals (CASI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics addressing cancer and other unmet medical needs. The company operates within the pharmaceutical and biotechnology sectors, offering a diverse portfolio of products that include both proprietary and in-licensed drugs. CASI's core product line includes oncology treatments and specialty therapeutics aimed at enhancing patient outcomes in China and other select markets.

How the Company Makes Money

CASI Pharmaceuticals generates revenue through the commercialization of its pharmaceutical products, primarily focusing on oncology and specialty therapeutics. The company's revenue streams include the direct sale of its developed drugs and in-licensed products to healthcare providers and distributors. Additionally, CASI may engage in strategic partnerships and collaborations with other pharmaceutical firms to co-develop or co-market products, providing additional income through milestone payments, royalties, and licensing fees. Factors such as regulatory approvals, market penetration, and product performance in clinical settings significantly influence CASI's earnings.

CASI Pharmaceuticals Financial Statement Overview

Summary

CASI Pharmaceuticals is facing significant financial challenges. The income statement shows a consistent decline in revenue with negative margins. The balance sheet indicates high leverage and shrinking equity, but liquidity is partly cushioned by cash reserves. Cash flows are under pressure with persistent negative free cash flow and inefficiencies in converting sales into cash.

Income Statement

CASI Pharmaceuticals has experienced a consistent decline in total revenue, from $43.1M in 2022 to $28.5M in 2024, indicating a negative revenue growth trend. The company also has negative EBIT and net income, leading to negative profit margins. These factors contribute to a weak income statement performance.

Balance Sheet

The balance sheet shows high leverage with a debt-to-equity ratio increasing to 11.96 in 2024, indicating significant financial risk. Stockholders' equity has drastically decreased over the years. However, the company maintains a significant portion of its assets in cash and cash equivalents, which provides some liquidity cushion.

Cash Flow

Cash flow from operations is consistently negative, leading to negative free cash flow. The company's free cash flow has deteriorated over time, growing more negative from $-26.7M in 2022 to $-29.5M in 2024. While financing activities have provided some cash inflow, this is not sustainable long-term. The operating cash flow to net income ratio is poor, reflecting inefficiencies in converting sales into cash.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
21.27M	28.54M	33.88M	43.11M	30.17M	15.14M
	Gross Profit
11.74M	11.15M	20.05M	27.28M	17.61M	5.63M
	EBIT
-36.67M	-39.62M	-25.08M	-26.49M	-35.28M	-33.31M
	EBITDA
-31.07M	-34.87M	-21.54M	-24.07M	-32.75M	-31.35M
	Net Income Common Stockholders
-30.35M	-39.26M	-26.94M	-39.41M	-37.77M	-62.57M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
13.94M	16.09M	30.77M	51.34M	48.57M	66.37M
	Total Assets
14.52M	53.67M	75.27M	96.23M	138.30M	127.73M
	Total Debt
1.47M	22.14M	21.24M	1.34M	2.17M	1.29M
	Net Debt
-12.47M	8.67M	4.16M	-45.77M	-36.54M	-55.77M
	Total Liabilities
9.89M	51.82M	51.10M	29.30M	30.34M	24.16M
	Stockholders Equity
4.64M	1.85M	24.16M	44.57M	84.50M	81.54M
Cash Flow		Free Cash Flow
0.00	-29.46M	-22.21M	-26.70M	-42.34M	-45.21M
	Operating Cash Flow
0.00	-29.22M	-19.97M	-21.09M	-26.84M	-25.89M
	Investing Cash Flow
0.00	11.24M	-9.67M	31.16M	-20.69M	-20.72M
	Financing Cash Flow
0.00	15.43M	-907.00K	-3.27M	29.64M	47.15M

CASI Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.87
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CASI, the sentiment is Negative. The current price of 1.87 is below the 20-day moving average (MA) of 1.90, below the 50-day MA of 2.03, and below the 200-day MA of 3.86, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 45.77 is Neutral, neither overbought nor oversold. The STOCH value of 55.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CASI.

CASI Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.14B	3.23	-45.01%	2.85%	17.55%	-0.69%
MDAI	45 Neutral	$37.59M	―	256.43%	―	238.96%	35.96%
CASI	41 Neutral	$28.97M	―	-1094.50%	―	11.40%	-18.18%
CLGN	41 Neutral	$22.11M	―	-79.46%	―	-95.30%	-135.89%
PYPD	41 Neutral	$28.33M	―	-853.05%	―	―	34.97%
GBIO	41 Neutral	$24.81M	―	-70.06%	―	146.47%	57.85%
FEMY	39 Underperform	$28.33M	―	-239.87%	―	61.97%	-6.89%